12:00 AM
 | 
Apr 11, 2011
 |  BC Week In Review  |  Company News  |  Other News

Arrowhead endocrine news

Arrowhead increased its stake in its Ablaris Therapeutics Inc. subsidiary to 64% from 55% after investing an additional $800,000 in the subsidiary in the...

Read the full 96 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >